Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity

Immunological Reviews

Volumn 268, Issue 1, 2015, Pages 311-327

  van Egmond, Marjolein ^a   Vidarsson, Gestur ^b   Bakema, Jantine E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antibody; Cancer; Cytokine; Fc receptors; Inflammation; TLR

Indexed keywords

CETUXIMAB; FC RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR; LECTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; RESIQUIMOD; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RITUXIMAB; SCAVENGER RECEPTOR C; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN; PATTERN RECOGNITION RECEPTOR; PROTEIN BINDING;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE ACTIVATION; BASOPHIL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROHN DISEASE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EOSINOPHIL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOPATHOLOGY; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INFECTION; INFLAMMATION; MACROPHAGE; MAST CELL; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; OLIGOMERIZATION; OPSONIZATION; PHAGOCYTOSIS; PLASMA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY IMMUNE RESPONSE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY; IMMUNOGLOBULINS; INFECTION; INFLAMMATION; NEOPLASMS; PROTEIN BINDING; RECEPTORS, FC; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84945292492     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12333     Document Type: Review

References (107)

1. Ademokun AA, Dunn-Walters D. Immune Responses: Primary and Secondary. Hoboken, NJ: Encyclopedia of Life Sciences, 2010.
2. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol 2015;16:343-353.
3. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
4. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-384.
5. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-820.
6. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006;24:19-28.
7. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev 2008;8:34-47.
8. Nimmerjahn F, Ravetch JV. FcgammaRs in health and disease. Curr Top Microbiol Immunol 2010;350:105-125.
9. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014;5:520.
10. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annu Rev Immunol 2003;21:177-204.
11. Bruhns P, Fremont S, Daeron M. Regulation of allergy by Fc receptors. Curr Opin Immunol 2005;17:662-669.
12. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012;119:5640-5649.
13. De Nardo D. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine 2015;74:181-189.
14. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev 2007;7:179-190.
15. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-650.
16. Narayanan KB, Park HH. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis 2015;20:196-209.
17. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev 2013;13:453-460.
18. Oosting M, etal. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci USA 2014;111:E4478-E4484.
19. Deguine J, Barton GM. MyD88: a central player in innate immune signaling. F1000prime Rep 2014;6:97.
20. Brown J, Wang H, Hajishengallis GN, Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res 2011;90:417-427.
21. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010;236:265-275.
22. Ballow M. Primary immunodeficiency disorders: antibody deficiency. J Allergy Clin Immunol 2002;109:581-591.
23. Suzuki R, Scheffel J, Rivera J. New insights on the signaling and function of the high-affinity receptor for IgE. Curr Top Microbiol Immunol 2015;388:63-90.
24. Davis RS, Wang YH, Kubagawa H, Cooper MD. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci USA 2001;98:9772-9777.
25. Wilson TJ, Fuchs A, Colonna M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol 2012;188:4741-4745.
26. Gould HJ, etal. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003;21:579-628.
27. Ward ES, Ober RJ. Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol 2009;103:77-115.
28. Stapleton NM, etal. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun 2011;2:599.
29. Yoshida M, etal. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004;20:769-783.
30. Vidarsson G, etal. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006;108:3573-3579.
31. James LC. Intracellular antibody immunity and the cytosolic Fc receptor TRIM21. Curr Top Microbiol Immunol 2014;382:51-66.
32. Keeble AH, Khan Z, Forster A, James LC. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci USA 2008;105:6045-6050.
33. McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 2013;14:327-336.
34. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012;1253:170-180.
35. van Vliet SJ, Garcia-Vallejo JJ, van Kooyk Y. Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. Immunol Cell Biol 2008;86:580-587.
36. Garcia-Vallejo JJ, van Kooyk Y. The physiological role of DC-SIGN: a tale of mice and men. Trends Immunol 2013;34:482-486.
37. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci USA 2013;110:9868-9872.
38. Hamerman JA, Lanier LL. Inhibition of immune responses by ITAM-bearing receptors. Sci STKE 2006;2006:re1.
39. Blank U, Launay P, Benhamou M, Monteiro RC. Inhibitory ITAMs as novel regulators of immunity. Immunol Rev 2009;232:59-71.
40. Pfirsch-Maisonnas S, etal. Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci Signal 2011;4:ra24.
41. Ivashkiv LB. How ITAMs inhibit signaling. Sci Signal 2011;4:pe2.
42. Pasquier B, etal. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 2005;22:31-42.
43. Aloulou M, etal. IgG1 and IVIg induce inhibitory ITAM signaling through FcgammaRIII controlling inflammatory responses. Blood 2012;119:3084-3096.
44. den Dunnen J, etal. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcgammaRIIa in human dendritic cells. Blood 2012;120:112-121.
45. Bakema JE, etal. Antibody-opsonized bacteria evoke an inflammatory dendritic cell phenotype and polyfunctional Th cells by cross-talk between TLRs and FcRs. J Immunol 2015;194:1856-1866.
46. Vogelpoel LT, Baeten DL, de Jong EC, den Dunnen J. Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity. Front Immunol 2015;6:79.
47. Vogelpoel LT, etal. Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. Nat Commun 2014;5:5444.
48. Vogelpoel LT, etal. FcgammaRIIa cross-talk with TLRs, IL-1R, and IFNgammaR selectively modulates cytokine production in human myeloid cells. Immunobiology 2015;220:193-199.
49. Suurmond J, Dorjee AL, Knol EF, Huizinga TW, Toes RE. Differential TLR-induced cytokine production by human mast cells is amplified by FcvarepsilonRI triggering. Clin Exp Allergy 2015;45:788-796.
50. Suurmond J, etal. Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Ann Rheum Dis 2014;74:1915-1923.
51. Suurmond J, Stoop JN, Rivellese F, Bakker AM, Huizinga TW, Toes RE. Activation of human basophils by combined toll-like receptor- and FcepsilonRI-triggering can promote Th2 skewing of naive T helper cells. Eur J Immunol 2014;44:386-396.
52. Banchereau J, etal. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
53. van Vliet SJ, den Dunnen J, Gringhuis SI, Geijtenbeek TB, van Kooyk Y. Innate signaling and regulation of dendritic cell immunity. Curr Opin Immunol 2007;19:435-440.
54. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev 2003;3:984-993.
55. Liew FY. T(H)1 and T(H)2 cells: a historical perspective. Nat Rev 2002;2:55-60.
56. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev 2002;2:933-944.
57. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev 2004;4:841-855.
58. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008;38:2636-2649.
59. van der Steen L, etal. Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology 2009;137:2018-2029.
60. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-265.
61. Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 2012;4:6049-6068.
62. Dennehy KM, etal. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol 2008;38:500-506.
63. Dennehy KM, Willment JA, Williams DL, Brown GD. Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling pathways. Eur J Immunol 2009;39:1379-1386.
64. Ferwerda G, Meyer-Wentrup F, Kullberg BJ, Netea MG, Adema GJ. Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell Microbiol 2008;10:2058-2066.
65. Goodridge HS, Underhill DM. Fungal recognition by TLR2 and dectin-1. Handb Exp Pharmacol 2008;183:87-109.
66. Gringhuis SI, den Dunnen J, Litjens M, van Het Hof B, van Kooyk Y, Geijtenbeek TB. C-type lectin DC-SIGN modulates Toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 2007;26:605-616.
67. Roe K, Gibot S, Verma S. Triggering receptor expressed on myeloid cells-1 (TREM-1): a new player in antiviral immunity? Front Microbiol 2014;5:627.
68. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000;164:4991-4995.
69. Hu LT, etal. Role of TREM-1 in response to Aspergillus fumigatus infection in corneal epithelial cells. Int Immunopharmacol 2014;23:288-293.
70. Bezbradica JS, Rosenstein RK, DeMarco RA, Brodsky I, Medzhitov R. A role for the ITAM signaling module in specifying cytokine-receptor functions. Nat Immunol 2014;15:333-342.
71. Ivashkiv LB. A signal-switch hypothesis for cross-regulation of cytokine and TLR signalling pathways. Nat Rev 2008;8:816-822.
72. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012;5:3-11.
73. Li M, Zhou Y, Feng G, Su SB. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr Mol Med 2009;9:365-374.
74. el Bannoudi H, Ioan-Facsinay A, Toes RE. Bridging autoantibodies and arthritis: the role of Fc receptors. Curr Top Microbiol Immunol 2014;382:303-319.
75. Segura E, etal. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013;38:336-348.
76. Xu XR, Liu CQ, Feng BS, Liu ZJ. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014;20:3255-3264.
77. Duerr RH, etal. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-1463.
78. Bakema JE, van Egmond M. The human immunoglobulin A Fc receptor FcalphaRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol 2011;4:612-624.
79. Hernandez-Pedro NY, Espinosa-Ramirez G, de la Cruz VP, Pineda B, Sotelo J. Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol 2013;2013:413465.
80. Weber MS, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011;1812:239-245.
81. O'Connor RA, etal. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008;181:3750-3754.
82. Codarri L, etal. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011;12:560-567.
83. El-Behi M, etal. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011;12:568-575.
84. Waldner H. The role of innate immune responses in autoimmune disease development. Autoimmun Rev 2009;8:400-404.
85. Carty M, Bowie AG. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem Pharmacol 2011;81:825-837.
86. Touil T, Fitzgerald D, Zhang GX, Rostami A, Gran B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J Immunol 2006;177:7505-7509.
87. Bakema JE, van Egmond M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr Top Microbiol Immunol 2014;382:373-392.
88. Overdijk MB, Verploegen S, Bleeker WK, Parren PWHI. Role of IgG Fc receptors in monoclonal antibody therapy of cancer, chapter 13. In: Ackerman ME, Nimmerjahn F eds. Antibody Fc: Linking Adaptive and Innate Immunity. London, UK: Elsevier, 2014:239-255.
89. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate invivo cytotoxicity against tumor targets. Nat Med 2000;6:443-446.
90. Bibeau F, etal. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-1129.
91. Kohrt HE, etal. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012;4:511-527.
92. Bakema JE, van Egmond M. Immunoglobulin A: a next generation of therapeutic antibodies? mAbs 2011;3:352-361.
93. Braster R, O'Toole T, van Egmond M. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. Methods 2014;65:28-37.
94. Gul N, etal. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest 2014;124:812-823.
95. Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011;50:248-254.
96. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity tocancer. Annu Rev Immunol 2011;29:235-271.
97. Fridlender ZG, etal. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-194.
98. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants?. Cancer J 2010;16:382-391.
99. Connolly DJ, O'Neill LA. New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 2012;12:510-518.
100. + T-cells. Mol Immunol 2009;46:1084-1091.
101. Aranda F, etal. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 2014;3:e29179.
102. Roda JM, Parihar R, Carson WE 3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 2005;175:1619-1627.
103. Moreno M, etal. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 2008;272:70-76.
104. Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncoimmunology 2013;2:e24677.
105. + T cells. Cancer Immunol Immunother 2013;62:1347-1357.
106. Butchar JP, etal. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin Cancer Res 2010;16:2065-2075.
107. Lu H, etal. TLR2 agonist PSK activates humanNK cells and enhances the antitumoreffect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res 2011;17:6742-6753.